Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Qualcomm (NASDAQ:QCOM) Shares Plunge 10% After Hours — Here’s What Brokers Think

Qualcomm Inc. (NASDAQ:QCOM) shares declined sharply in after-hours trading on February 4 after the company reported its fiscal first-quarter 2026 results. Despite posting recordrevenues- the stock fell 9.68%,brokeragesissued cautious ratings and investors focused on forward guidance.

Sonal Goyal | 04 February 2026

Global Markets Snapshot: Earnings Drive U.S. Equity Gains as Commodities Stabilize and Macro Signals Remain Mixed

U.S. equities were set to open higher, with the S&P 500 above 7,000 and the Dow and Nasdaq up around 0.5%, as investor focus shifted back to earnings. Tech and AI stocks led gains, with Palantir jumping over 10% on upbeat 2026 guidance, strength …

Team Kalkine | 03 February 2026

Palantir Stock Jumps 10% Premarket After Q4 Earnings Beat.

Imagine a company born from post-9/11 intelligence needs, now powering supply chain miracles for the world's largest corporations. Palantir's Artificial Intelligence Platform (AIP) – with its ontology-centric architecture – has cracked the code on enterprise AI deployment. Q4 marked the inflection: U.S. commercial revenue …

Team Kalkine | 03 February 2026

ServiceNow (NYSE:NOW) Gains After Inclusion on Major Bank Conviction List

After showing weakness toward the end of the previous week, ServiceNow (NYSE:NOW) shares moved modestly higher on Monday. The stock closed the session up just under 1%, outperforming the broader market, which posted a smaller gain on the day. Investor sentiment appeared to improve …

Aditi Sarkar | 03 February 2026

What Drove Columbia Financial’s (NASDAQ:CLBK) 9% Stock Move on Monday?

Columbia Financial (NASDAQ:CLBK) experienced an active trading session after releasing its latest financial results alongside news of a planned acquisition. Shares rose by nearly 9% during the session, reflecting market response to both the earnings update and the strategic transaction announcement.

Aditi Sarkar | 03 February 2026

Should You Hold This Dividend Mining Stock After Its 2025 Rally?

Hecla Mining (NYSE:HL) operates as a precious metals producer with a primary focus on silver. During the third quarter of 2025, silver accounted for roughly half of company revenue, while gold represented just over one-third. Lead and zinc contributed the remainder. As a result, …

Aditi Sarkar | 03 February 2026

Is Corning (NYSE:GLW) a Buy After Its USD 6 Bn Meta AI Deal?

Corning Incorporated (NYSE:GLW) has long been associated with specialty glass products used in consumer electronics. Over recent years, however, the company has increased its exposure to optical communications, supplying fiber-optic cables used in data centres and enterprise networks. These products are designed to transmit …

Aditi Sarkar | 03 February 2026

NVIDIA Corp (NASDAQ:NVDA) Tracks AI-Led Demand Amid Market Swings

NVIDIA Corp (NASDAQ:NVDA) operates in the semiconductor sector, designing graphics processing units that enable parallel computing. While GPUs were initially developed for gaming graphics, their architecture has made them suitable for tasks requiring large-scale computational power. Over time, these processors have been adopted for …

Aditi Sarkar | 03 February 2026

SouthState Bank (NYSE:SSB) Sees Analyst Target Revisions Amid Shifting Share Price Trends

SouthState Bank (NYSE:SSB) is a U.S.-based bank holding company headquartered in Winter Haven, Florida. Through its primary subsidiary, SouthState Bank, the company provides commercial and retail banking services to businesses, institutions, and individual customers. Its core activities include commercial and industrial lending, commercial real …

Aditi Sarkar | 03 February 2026

Protagonist Therapeutics (NASDAQ: PTGX) Under the Lens: How Do Analyst Targets Compare With Recent Price Trends?

Protagonist Therapeutics (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company focused on developing orally administered peptide-based therapies for immune-mediated and other serious diseases. The company applies its proprietary Peptide 2.0 platform to design molecules targeting G protein–coupled receptors and cytokine receptors, aiming to provide oral alternatives …

Aditi Sarkar | 03 February 2026
Support

Hi! How can we help you today?

Loading…